2026 Q1 -tulosraportti
103 päivää sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sitten · MuokattuThere's a lot written in here about price levels for Egetis for the period leading up to Sep. 28th, I myself am one of several writers. What I most recently wrote about price-action for Egetis actually unfolded - I suggested that the case just needed to retrace down into the area <6ish down to 5.80ish>. The case bottomed out at price 5.86. What happened was that Egetis hit an old top in the ongoing trading-range, showed weakness - after which it logically should retrace Fib50 to a level which was also medium-term support - and it played out exactly as assumed. Pure simple coincidence many might say - which is completely legitimate - no one can see into the future, not even yours truly! I took advantage of the now completed retrace to buy the case for my portfolio, and I'm not done buying - more shares are needed. In this context, I can also mention that in the trading system I had placed a stop-loss BUY order for activation at price 5.84 which naturally was NOT triggered, - as price-action bottomed out at price 5.86. That's how small margins can sometimes go against you :o) The next area that will be interesting to observe price-action in is just around the corner at price 7.4ish - here lie several old tops and bottoms - in the trading-range the case has now been in for the past approx. 6 years. Should price-action not have enough momentum, then a 'poke-up' in the price 7.4ish area will result in a new retrace down towards 6.6-6.4ish, before it probably seeks higher up again towards end-Sep. So right now I'm sitting on my hands and waiting for the price 7.4ish area to be hit. If price-action makes a break up through this area, 7.4<>7.6 - and immediately makes closing prices in / above this area - then momentum is strong and the case can be bought at current market price. If it shows weakness in this area, the case can be accumulated in a retrace that brings it down around price 6.6<>6.4ish again, before further ascent. Finally, a suggestion for the further price-action leading up to Sep. 28th. In my view, one should be prepared for profit-taking towards Sep. 28th, because in 99 out of 100 cases, that's what happens in price-action cases similar to this Egetis case. If the case just plays out somewhat bob-bob somewhat in the style of what I describe here - then there are still several 'low-hanging entries' to trade into the case leading up to Sep. 28th.
·2 päivää sittenFor once, Egetis rpt August 21 doesn't feel so important. Probably limited growth, good cash position, and All eyes on FDA. What do you others think?
Completely agree. Good to see that we finally pass 7kr too. I believe the price will continue upwards towards 8-9 kr until the FDA decision.
·5.8.Much speaks for approval, here is additional useful information that supports that reasoning. FDA's orphan-PDUFA 2025 – how many were actually approved? Compilation of orphan drugs with PDUFA decisions in 2025 with controlled outcome against FDA approvals. Results: - Total number of orphan-PDUFA: 43 - Approved: 37 - Complete Response Letter (CRL): 6 Approval rate: - 37 out of 43 = 86.0 % The figure of 83.7 % (36/43) sometimes mentioned is based on one drug still having a delayed PDUFA decision when the compilation was first made. That drug was: - Sebetralstat (Ekterly) – KalVista Pharmaceuticals The FDA extended the review because supplementary information had been submitted late. It was not a Complete Response Letter (CRL) and not a rejection. Subsequently, the drug was approved by the FDA on July 3, 2025. This means that the final result for 2025 was: - 37 approved - 6 CRL - 0 remaining postponed decisions Conclusion: The historical approval rate for orphan drugs with PDUFA decisions in 2025 was thus 86.0 %. Sources: - CheckRare – 2025 Orphan Drugs: PDUFA Dates and FDA Approvals (compilation of all orphan-PDUFA during the year). - FDA Orphan Drug Database – confirms that sebetralstat (Ekterly) was approved on July 3, 2025.- ·5.8.Is this when the speculative run-up starts before pdufa and we truly break out, towards 8-10kr before? Go egetis what strength with good volume lately
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
103 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sitten · MuokattuThere's a lot written in here about price levels for Egetis for the period leading up to Sep. 28th, I myself am one of several writers. What I most recently wrote about price-action for Egetis actually unfolded - I suggested that the case just needed to retrace down into the area <6ish down to 5.80ish>. The case bottomed out at price 5.86. What happened was that Egetis hit an old top in the ongoing trading-range, showed weakness - after which it logically should retrace Fib50 to a level which was also medium-term support - and it played out exactly as assumed. Pure simple coincidence many might say - which is completely legitimate - no one can see into the future, not even yours truly! I took advantage of the now completed retrace to buy the case for my portfolio, and I'm not done buying - more shares are needed. In this context, I can also mention that in the trading system I had placed a stop-loss BUY order for activation at price 5.84 which naturally was NOT triggered, - as price-action bottomed out at price 5.86. That's how small margins can sometimes go against you :o) The next area that will be interesting to observe price-action in is just around the corner at price 7.4ish - here lie several old tops and bottoms - in the trading-range the case has now been in for the past approx. 6 years. Should price-action not have enough momentum, then a 'poke-up' in the price 7.4ish area will result in a new retrace down towards 6.6-6.4ish, before it probably seeks higher up again towards end-Sep. So right now I'm sitting on my hands and waiting for the price 7.4ish area to be hit. If price-action makes a break up through this area, 7.4<>7.6 - and immediately makes closing prices in / above this area - then momentum is strong and the case can be bought at current market price. If it shows weakness in this area, the case can be accumulated in a retrace that brings it down around price 6.6<>6.4ish again, before further ascent. Finally, a suggestion for the further price-action leading up to Sep. 28th. In my view, one should be prepared for profit-taking towards Sep. 28th, because in 99 out of 100 cases, that's what happens in price-action cases similar to this Egetis case. If the case just plays out somewhat bob-bob somewhat in the style of what I describe here - then there are still several 'low-hanging entries' to trade into the case leading up to Sep. 28th.
- ·2 päivää sittenFor once, Egetis rpt August 21 doesn't feel so important. Probably limited growth, good cash position, and All eyes on FDA. What do you others think?Completely agree. Good to see that we finally pass 7kr too. I believe the price will continue upwards towards 8-9 kr until the FDA decision.
- ·5.8.Much speaks for approval, here is additional useful information that supports that reasoning. FDA's orphan-PDUFA 2025 – how many were actually approved? Compilation of orphan drugs with PDUFA decisions in 2025 with controlled outcome against FDA approvals. Results: - Total number of orphan-PDUFA: 43 - Approved: 37 - Complete Response Letter (CRL): 6 Approval rate: - 37 out of 43 = 86.0 % The figure of 83.7 % (36/43) sometimes mentioned is based on one drug still having a delayed PDUFA decision when the compilation was first made. That drug was: - Sebetralstat (Ekterly) – KalVista Pharmaceuticals The FDA extended the review because supplementary information had been submitted late. It was not a Complete Response Letter (CRL) and not a rejection. Subsequently, the drug was approved by the FDA on July 3, 2025. This means that the final result for 2025 was: - 37 approved - 6 CRL - 0 remaining postponed decisions Conclusion: The historical approval rate for orphan drugs with PDUFA decisions in 2025 was thus 86.0 %. Sources: - CheckRare – 2025 Orphan Drugs: PDUFA Dates and FDA Approvals (compilation of all orphan-PDUFA during the year). - FDA Orphan Drug Database – confirms that sebetralstat (Ekterly) was approved on July 3, 2025.
- ·5.8.Is this when the speculative run-up starts before pdufa and we truly break out, towards 8-10kr before? Go egetis what strength with good volume lately
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
103 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sitten · MuokattuThere's a lot written in here about price levels for Egetis for the period leading up to Sep. 28th, I myself am one of several writers. What I most recently wrote about price-action for Egetis actually unfolded - I suggested that the case just needed to retrace down into the area <6ish down to 5.80ish>. The case bottomed out at price 5.86. What happened was that Egetis hit an old top in the ongoing trading-range, showed weakness - after which it logically should retrace Fib50 to a level which was also medium-term support - and it played out exactly as assumed. Pure simple coincidence many might say - which is completely legitimate - no one can see into the future, not even yours truly! I took advantage of the now completed retrace to buy the case for my portfolio, and I'm not done buying - more shares are needed. In this context, I can also mention that in the trading system I had placed a stop-loss BUY order for activation at price 5.84 which naturally was NOT triggered, - as price-action bottomed out at price 5.86. That's how small margins can sometimes go against you :o) The next area that will be interesting to observe price-action in is just around the corner at price 7.4ish - here lie several old tops and bottoms - in the trading-range the case has now been in for the past approx. 6 years. Should price-action not have enough momentum, then a 'poke-up' in the price 7.4ish area will result in a new retrace down towards 6.6-6.4ish, before it probably seeks higher up again towards end-Sep. So right now I'm sitting on my hands and waiting for the price 7.4ish area to be hit. If price-action makes a break up through this area, 7.4<>7.6 - and immediately makes closing prices in / above this area - then momentum is strong and the case can be bought at current market price. If it shows weakness in this area, the case can be accumulated in a retrace that brings it down around price 6.6<>6.4ish again, before further ascent. Finally, a suggestion for the further price-action leading up to Sep. 28th. In my view, one should be prepared for profit-taking towards Sep. 28th, because in 99 out of 100 cases, that's what happens in price-action cases similar to this Egetis case. If the case just plays out somewhat bob-bob somewhat in the style of what I describe here - then there are still several 'low-hanging entries' to trade into the case leading up to Sep. 28th.
- ·2 päivää sittenFor once, Egetis rpt August 21 doesn't feel so important. Probably limited growth, good cash position, and All eyes on FDA. What do you others think?Completely agree. Good to see that we finally pass 7kr too. I believe the price will continue upwards towards 8-9 kr until the FDA decision.
- ·5.8.Much speaks for approval, here is additional useful information that supports that reasoning. FDA's orphan-PDUFA 2025 – how many were actually approved? Compilation of orphan drugs with PDUFA decisions in 2025 with controlled outcome against FDA approvals. Results: - Total number of orphan-PDUFA: 43 - Approved: 37 - Complete Response Letter (CRL): 6 Approval rate: - 37 out of 43 = 86.0 % The figure of 83.7 % (36/43) sometimes mentioned is based on one drug still having a delayed PDUFA decision when the compilation was first made. That drug was: - Sebetralstat (Ekterly) – KalVista Pharmaceuticals The FDA extended the review because supplementary information had been submitted late. It was not a Complete Response Letter (CRL) and not a rejection. Subsequently, the drug was approved by the FDA on July 3, 2025. This means that the final result for 2025 was: - 37 approved - 6 CRL - 0 remaining postponed decisions Conclusion: The historical approval rate for orphan drugs with PDUFA decisions in 2025 was thus 86.0 %. Sources: - CheckRare – 2025 Orphan Drugs: PDUFA Dates and FDA Approvals (compilation of all orphan-PDUFA during the year). - FDA Orphan Drug Database – confirms that sebetralstat (Ekterly) was approved on July 3, 2025.
- ·5.8.Is this when the speculative run-up starts before pdufa and we truly break out, towards 8-10kr before? Go egetis what strength with good volume lately
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt